snoooop40
Long

Inovio Pharmaceuticals Provides another great entry opportunity

374 1 0
Inovio announced (July 23 / 2014) HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial. The price per share closed today @ $12.63, that's 11% lower than the post-announcement high of $14.20 and 20% lower than the 52 week high of $15.80.
As the market digests this HUGE news and we await "detailed study findings will be submitted for publication in a peer-reviewed scientific journal", I would expect to see some extreme volatility to continue.
I have a long position ACB $8.20 and I actively swing-trade as opportunities arise. Pull-back(s) such as where we are now are the opportunities I seek.
I expect to see many upgrades in the near future and the possibility(s) of partnerships could be announced anytime. As with any small-cap bio stock , dilution is a possibility in order to fund ongoing phase 1 & 2 clinical trials or future phase 3 trials.
**Note** I am particularly interested in the possibility of a gap (getting filled) that formed on the daily chart on July 23rd (phase 2 data released) @ $11.60 - $12.00.
Hope you enjoy the chart and have great trades in the future.
snoooop40
2 years ago
Correction on the date of The Street Article. It was actually posted on June 10th 2014. The fall in price during Mar & Apr is most likely associated with the announcement of the reverse stock split.
Reply
Ideas Scripts Chart
United States
United Kingdom
India
España
Italia
Brasil
Россия
Türkiye
日本
한국
Home Stock Screener Economic Calendar How It Works Chart Features House Rules Moderators For the WEB Widgets Stock Charting Library Priority Support Feature Request Blog & News FAQ Help & Wiki Twitter
Private Messages Chat Ideas Published Followers Following Priority Support Public Profile Profile Settings Billing Sign Out